Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
Takeda Pharmaceutical is in talks with the European Commission (EC) about the possible sale of Shire’s GI drug candidate SHP647 so as to iron out a future overlap in their portfolio and clear the last antitrust hurdle to its proposed…
To read the full story
Related Article
- Takeda Winds Up Development of IBD Drug SHP647
June 1, 2020
- Takeda Earns Japan Clearance for Shire Acquisition
October 19, 2018
- Takeda Gets China OK for Shire Takeover
September 18, 2018
- Takeda Clinches Key US Clearance for Shire Takeover
July 10, 2018
- Takeda Inks US$7.5 billion Term Loan Credit to Refinance M&A Bridge
June 11, 2018
BUSINESS
- Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Expert Highlights Subcutaneous Benefits of Rybrofaz in Lung Cancer
April 6, 2026
- NEC Bio, Transgene Strike Licensing Deal for Cancer Vaccine
April 6, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…